E-ISSN 2367-699X | ISSN 2367-7414
 
2023, Vol: 9, Issue: 5
9 / 5Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Copyright Transfer Form

Review Article

Online Publishing Date:
30 / 04 / 2016

 


HORMONE THERAPY IN ADVANCED ER+/HER2- NEGATIVE BREAST CANCER WITH PI3K INHIBITORS: A REVIEW OF THE LITERATURE

Ivan Inkov, Desislava Penkova, George Baytchev, Zdravko Kamenov, Mila Kayryakova, Dimo Manov.


Cited By: 1

Abstract
Breast cancer is a heterogenous disease, showing as several different clinical and histologic types. Most of breast cancers express hormone receptors for estrogen and progesterone, which are considered as estrogen receptor-positive and progesterone-receptor-positive, respectively.
Endocrine therapy was the first class of target-directed therapy approved for treating breast cancer and is still very important for the treatment of HR+ breast cancer because of its effectiveness and good toxicity profile. It targets receptor-mediated signaling pathways implicated in cell survival and proliferation, such as those mediated by hormone receptors. Although these approaches have improved the management of advanced breast cancer, many patients either fail to respond to initial therapy (primary or de novo resistance) or eventually become resistant to treatment (secondary or acquired resistance). To expand the use of existing endocrine treatments and their efficiency, new methods are needed. Such new approaches would boost the benefit of existing endocrine therapy by extending time to disease progression, avoiding or overcoming resistance to endocrine treatment, and delaying the use of chemotherapy.
This article will review the central role of the PI3K inhibitors in driving ER+/HER2- breast tumors. Also, schemes to combine pathway inhibitors with endocrine therapy for better patient outcome, and approaches to identify patient populations that would benefit most from inhibition of the PI3K/AKT/mTOR pathway will be assessed.

Key words: pi3k inhibitors breast cancer, buparlisib belle2, hr+ her2- negative pi3k


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Ivan Inkov
Articles by Desislava Penkova
Articles by George Baytchev
Articles by Zdravko Kamenov
Articles by Mila Kayryakova
Articles by Dimo Manov
on Google
on Google Scholar


This Article Cited By the following articles

New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells
Bioorganic Chemistry 2021; 115(): 105208.

1
 
How to Cite this Article
Pubmed Style

Ivan Inkov, Desislava Penkova, George Baytchev, Zdravko Kamenov, Mila Kayryakova, Dimo Manov. HORMONE THERAPY IN ADVANCED ER+/HER2- NEGATIVE BREAST CANCER WITH PI3K INHIBITORS: A REVIEW OF THE LITERATURE. Int J Surg Med. 2016; 2(2): 68-76. doi:10.5455/ijsm.pi3kinhibitorbreastcancer

Web Style

Ivan Inkov, Desislava Penkova, George Baytchev, Zdravko Kamenov, Mila Kayryakova, Dimo Manov. HORMONE THERAPY IN ADVANCED ER+/HER2- NEGATIVE BREAST CANCER WITH PI3K INHIBITORS: A REVIEW OF THE LITERATURE. https://www.ejos.org/?mno=227219 [Access: February 20, 2024]. doi:10.5455/ijsm.pi3kinhibitorbreastcancer

AMA (American Medical Association) Style

Ivan Inkov, Desislava Penkova, George Baytchev, Zdravko Kamenov, Mila Kayryakova, Dimo Manov. HORMONE THERAPY IN ADVANCED ER+/HER2- NEGATIVE BREAST CANCER WITH PI3K INHIBITORS: A REVIEW OF THE LITERATURE. Int J Surg Med. 2016; 2(2): 68-76. doi:10.5455/ijsm.pi3kinhibitorbreastcancer


Vancouver/ICMJE Style

Ivan Inkov, Desislava Penkova, George Baytchev, Zdravko Kamenov, Mila Kayryakova, Dimo Manov. HORMONE THERAPY IN ADVANCED ER+/HER2- NEGATIVE BREAST CANCER WITH PI3K INHIBITORS: A REVIEW OF THE LITERATURE. Int J Surg Med. (2016), [cited February 20, 2024]; 2(2): 68-76. doi:10.5455/ijsm.pi3kinhibitorbreastcancer


Harvard Style

Ivan Inkov, Desislava Penkova, George Baytchev, Zdravko Kamenov, Mila Kayryakova, Dimo Manov (2016) HORMONE THERAPY IN ADVANCED ER+/HER2- NEGATIVE BREAST CANCER WITH PI3K INHIBITORS: A REVIEW OF THE LITERATURE. Int J Surg Med, 2 (2), 68-76. doi:10.5455/ijsm.pi3kinhibitorbreastcancer


Turabian Style

Ivan Inkov, Desislava Penkova, George Baytchev, Zdravko Kamenov, Mila Kayryakova, Dimo Manov. 2016. HORMONE THERAPY IN ADVANCED ER+/HER2- NEGATIVE BREAST CANCER WITH PI3K INHIBITORS: A REVIEW OF THE LITERATURE. International Journal of Surgery and Medicine, 2 (2), 68-76. doi:10.5455/ijsm.pi3kinhibitorbreastcancer


Chicago Style

Ivan Inkov, Desislava Penkova, George Baytchev, Zdravko Kamenov, Mila Kayryakova, Dimo Manov. "HORMONE THERAPY IN ADVANCED ER+/HER2- NEGATIVE BREAST CANCER WITH PI3K INHIBITORS: A REVIEW OF THE LITERATURE." International Journal of Surgery and Medicine 2 (2016), 68-76. doi:10.5455/ijsm.pi3kinhibitorbreastcancer


MLA (The Modern Language Association) Style

Ivan Inkov, Desislava Penkova, George Baytchev, Zdravko Kamenov, Mila Kayryakova, Dimo Manov. "HORMONE THERAPY IN ADVANCED ER+/HER2- NEGATIVE BREAST CANCER WITH PI3K INHIBITORS: A REVIEW OF THE LITERATURE." International Journal of Surgery and Medicine 2.2 (2016), 68-76. Print. doi:10.5455/ijsm.pi3kinhibitorbreastcancer


APA (American Psychological Association) Style

Ivan Inkov, Desislava Penkova, George Baytchev, Zdravko Kamenov, Mila Kayryakova, Dimo Manov (2016) HORMONE THERAPY IN ADVANCED ER+/HER2- NEGATIVE BREAST CANCER WITH PI3K INHIBITORS: A REVIEW OF THE LITERATURE. International Journal of Surgery and Medicine, 2 (2), 68-76. doi:10.5455/ijsm.pi3kinhibitorbreastcancer


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessAuthor's Rights and ObligationsPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About International Journal of Surgery and Medicine

International Journal of Surgery and Medicine E-ISSN: 2367-699X | P-ISSN: 2367-7414 International Journal of Surgery and Medicine (IJSM) is an inter ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


 

Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the International Journal of Surgery and Medicine editorial office as follows:

Bulgarian Association of Young Surgeons (BAYS)

inkov@journalmedica.com

Financial department is managed by International Sci Ink Press. 

It is a company registered in Bulgaria with registered no. 205414288 and registered address at 57 Antim I str., Vazrazhdane, Sofia, 1303, Bulgaria.

Tel: +359883427500